Explore the Agenda
8:00 am Check In & Coffee
8:20 am Chair’s Opening Remarks
Advancing Combinations & Novel Targets to Expand Therapeutic Horizons in Solid Tumors
8:30 am Combining Tarlatamab with Chemo-immunotherapy to Kick-Start a New Era in Small Cell Lung Cancer Treatment
- Tracing the breakthrough journey of tarlatamab from discovery to development, showcasing the scientific insights that enabled a first‑in‑class T‑cell–engager approach for SCLC
- Revealing the synergistic potential of pairing T‑cell engager molecules with checkpoint inhibitors and chemotherapy, supported by compelling preclinical evidence that demonstrates enhanced anti‑tumour activity and immune activation
- Highlighting emerging clinical data on tarlatamab and chemo‑immunotherapy combinations, illustrating how this strategy may unlock deeper, more durable responses for patients with limited treatment options
9:00 am Advancing Immuno‑Oncology Breakthroughs & Reducing Toxicity Risks Through Next‑Generation Preclinical Models
- Discovering how strategic combination approaches can meaningfully elevate the therapeutic power of CD3 bispecifics, driving stronger, more durable T‑cell responses, improving tumor clearance, and overcoming resistance mechanisms that limit efficacy in current therapies
- Gaining insights into cutting‑edge preclinical methods designed to minimize cytokine‑driven toxicity and on‑target/off‑tumour effects
- Understanding how engineering innovations, conditional activation formats, and optimized dosing strategies can expand therapeutic windows and improve the safety profile of next‑generation immunotherapies
9:30 am Session Reserved for Alloy Therapeutics
10:00 am Advancing PRAME pMHC Targeted T-Cell Engager for Solid Tumor Therapy
- Bispecific T‑cell engagers have shown strong clinical success in hematologic cancers, but their use in solid tumors is limited by the lack of antigens that are sufficiently selective to avoid on‑target, off‑tumor toxicity
- PRAME, a cancer‑testis antigen with highly tumor‑restricted expression, was identified as a promising solid‑tumor TCE target, and the PRAME₄₂₅ peptide presented by MHC‑I was validated as an attractive pMHC epitope for selective targeting
- Novel antiPRAME₄₂₅ pMHC antibodies were discovered that specifically recognize the PRAME₄₂₅–MHC complex without binding to MHC alone or unrelated pMHCs, and when formatted into TCEs, they drive PRAME₄₂₅specific tumor cell killing—establishing a new class of antiPRAME pMHC biologics
10:30 am Exploring the De novo Design and Hypothesis-Driven exploration of Potent T-cell Engagers with JAM-2
- Exploring how generative design enables the rational construction of multispecifics
- Rapid generation of developable TCEs by designing in developability
- Exploration of new target space for TAAs including complex multipass membrane proteins
- Rationale design of TCEs that optimize the immune synapse
11:00 am Morning Refreshments & Networking
Discovery, Design & Engineering
Advancing Masking Technology & Binder Selection to Improve Selective Activation & Maximize Tumor- Specific Engagement
11:30 am Discovery, Engineering and Optimization of a Bispecific T-Cell Engager Against a Novel Low Copy Number Tumor Antigen
- Discovery of the novel tumor antigen, focusing on the identification strategies used to validate its high tumor selectivity and the challenges associated with targeting a protein with such a low-copy-number expression profile
- Rational engineering of the bispecific scaffold, detailing the optimization of the CD3 and tumor-binding domains to ensure a stable immunological synapse can form even when target density is minimal
- Optimization of the therapeutic window, highlighting how binding affinities were fine-tuned to maximize T-cell mediated killing of tumor cells while mitigating the risks of off-tumor toxicity and systemic cytokine release.
12:00 pm PRO‑XTEN Masked T-Cell Engagers; A Novel Therapeutic Approach Enabling Protease‑Specific Activation of TCEs Only in the Tumor Microenvironment to Mitigate Damage to Healthy Tissues & Reduce Toxicity
- Exploring how engineering TCEs with protease-cleavable masks creates a molecular switch
- Discussing the protein engineering strategies at optimal masking architectures for TCEs
- Evaluating data on current clinical molecules using masking features and their potential to safely target high-expression antigens
Preclinical, Translational & Clinical Development
Leveraging Mechanistic Biomarkers to Refine Clinical Dosing Strategies & Ensure Patient Safety During TCE Administration
11:30 am Advancing T‑Cell Engagers Targeting Driver Mutations for Solid Tumors
- Discovery and engineering approaches for generating highly selective pHLA-targeted binders.
- Preclinical evaluation strategies, including functional activity, specificity, and safety assessment.
- Key learnings from advancing pHLA-targeted therapies from nonclinical development into the clinic, and implications for next-generation programs
12:00 pm Standardizing Step-Up Dosing Escalation Protocols to Master Early-Phase Safety and Maximize the Therapeutic Window of T-Cell Engagers
- Implementing evidence-based step-up dosing regimens to reduce the cytokine response, allowing for higher target doses while minimizing the risk of severe CRS and ICANS
- Transitioning to Modified MABEL models that utilize real-time PD markers to identify the optimal biological dose
- Ensuring escalation decisions are based on anti-tumor activity rather than just circulating drug levels
12:30 pm Lunch & Networking
Discovery, Design & Engineering
Utilizing Advanced Platforms to Engineer the Next Generation of Curative T-Cell Engagers
1:30 pm Advancing the EVOVLE Platform with Integrated CD2 Costimulation to Enhance the Depth of T-Cell Engager Responses and Prevent Early Therapeutic Exhaustion
- T‑cell engagers have shown positive clinical outcomes across multiple indications, including solid tumors, but currently approved molecules do not provide a direct co‑stimulatory signal
- The EVOLVE platform integrates CD2 co‑stimulation into CD3 multispecifics to enhance T‑cell activation, durability, and functional fitness
- An overview of the EVOLVE multispecific platform and highlight key design features that enable improved T‑cell engagement
2:00 pm XmAb819: Avidity-Driven Selectivity in T-Cell Engagers Using Xencor’s 2+1 Platform
- Discussing different T-Cell Engager configurations such as 1+1 and 2+1 as strategies for selectivity
- Examining how dual-antigen engagement enables simultaneously binding that increases functional avidity and exploring factors that impact avidity
- Presentation of pre-clinical and clinical data in RCC
2:30 pm Building Multi‑Specific T‑Cell Engagers for Heterogeneous, Hard‑to‑Treat Tumors
- A purpose‑built approach addresses the limiting challenges of narrow therapeutic windows and target heterogeneity by extending T‑cell engager success to pMHC targets.
- Trackers, small soluble TCR‑derived binding elements, leverage the natural pMHC–TCR interaction to drive precise tumor cell killing while maintaining antibody‑like developability.
- The Broadcast platform identifies optimal target pairs, discovers and optimizes novel Trackers with drug‑like properties, and designs multi‑specific formats that expand tumor coverage and increase the number of patients with potential to benefit
Preclinical, Translational & Clinical Development
Navigating Early Clinical Development of TCE Combination Therapies for Long‑Term Success
1:30 pm Panel Discussion: Adopting Human-Centric Alternative Models to Navigate the Global Shift Away from NHP Studies and De-Risk Immuno-Oncology Development
- Debating the reality on the ground for biotechs still being pushed for NHP data and managing the gap between progressive policy and conservative reviewer feedback
- Discussing perspectives from the EU, US and Asia around the strategic burden of conducting redundant animal studies to satisfy geographically distinct regulation
- Exploring how smaller biotechs ca balance high cost of NHP studies against the need for convincing data to secure funding, even when alternative models might gain FDA approval
2:00 pm Enhancing Efficacy of T-Cell Engagers in Solid Tumors with CD28 Co-Stimulation
- CD28 stimulation has the potential to provide more durable responses and activate T cell responses in cold tumors with low T cell infiltration.
- ZW209 is a DLL3-targeted multispecific T cell engagers leveraging cis co-stimulation of CD28 with favorable preclinical efficacy and tolerability.
- Our conditional CD28 co-stimulation platform can be combined with multiple geometries and tumor associated antigens to increase efficacy of T cell engagers in both solid and liquid tumors.
2:30 pm Rational Target Selection, Combination Design & Early Clinical Responses for TCEs
- How antigen density, tumor heterogeneity, and safety considerations guide the rational selection of TCE targets to maximize efficacy while minimizing off‑tumor toxicity
- Rationale for pairing TCEs with agents such as cytokine modulators, checkpoint inhibitors, and targeted therapies to enhance T‑cell activation, durability, and tumor penetration
- Emerging patterns in efficacy, safety, and biomarkers from first‑in‑human TCE studies, and what they reveal about translational design decisions
3:00 pm Afternoon Refreshments & Networking
Utilizing Immune Effector Cells to Unleash Next-Generation Precision Targeting & Overcome Traditional T-Cell Limitations
3:30 pm Unlocking Intracellular Targets Through Synapse-Optimised T cell Engagers
- Discover and validate novel MHC presented targets
- Optimize, in parallel, our TCR-Ab binders, our anti-CD3, and our format for optimal synapse formation and therapeutic window
4:00 pm Conditionally Active Costimulatory T Cell-Engager Programs for Autoimmunity & Solid-Tumor Indications
- Shifting from oncology’s maximum potency mindset to a safety-first model by optimizing immune thresholds for chronic B-cell or T-cell depletion
- Leveraging lessons from oncology to eliminate high-grade CRS and ICANS, ensuring a benign safety profile suitable for non-malignant, chronic indications
- Utilizing tissue-restricted targeting and refined dosing to achieve long-term immune reset while preserving overall patient safety
4:30 pm Panel Discussion: Utilizing Discovery Platforms to Hunt for the Perfect Target & Advance T-Cell Engager Efficacy in Solid & Liquid Tumors
- Discussing the methodologies currently used to identify antigens in multiple myeloma and B-cell lymphoma
- Debating whether therapeutic failure in hematologic cancers stems from T-cell exhaustion or from a lack of high-density, specific antigens to target
- Identifying shared antigens vs personalized neoantigens in solid tumor populations